vialauditThe Roundup
TESAMORELIN·US LEGAL STATUS·LAST CHECKED 12 OCT 2026

Is Tesamorelin legal?

Yes, as a prescription drug: FDA has approved it (Egrifta). A vial sold as a 'research peptide' is not the approved product, and selling it for human use breaks federal drug law. Pharmacies cannot compound it because it is regulated as a biologic.

RESEARCH-LABELLED SALE
Unapproved copy of an Rx drug
PHARMACY COMPOUNDING
No (biologic)
PRESCRIPTION
FDA-approved (Egrifta)
WADA 2026
Prohibited (S2.2.4)

DESCRIBES THE LAW · NOT LEGAL ADVICE · NO DOSING INFORMATION

Federal, compounding and sport status

CHECKED 12 OCT 2026

Federal status

FDA approval
approved as drug · brand: Egrifta, Egrifta SV, Egrifta WR · NDA 022505 · approved Nov 10, 2010
Indications: Reduction of excess abdominal fat in HIV lipodystrophy
DEA scheduling
not scheduled
503A compounding
FDA interim category: Component of an FDA-approved drug
503A Bulks List: not on list
Component of the approved Egrifta products. Tesamorelin moved to the biologics framework in March 2020, and 503A does not cover biological products, so pharmacy compounding of it is not available.
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Brand Egrifta is Rx-only; 'research-grade tesamorelin' from peptide retailers is unapproved and FDA's RUO posture rejection applies.
Personal possession: Lawfully obtained Rx Egrifta is lawful to possess. Unapproved compounded/research-source tesamorelin is at enforcement risk on the seller side.

Sport-body status

WADA 2026
prohibited · class S2.2.4 · in and out of competition
Named under S2.2.4 growth hormone releasing factors (GHRH analogues).
USADA
NCAA

What we couldn’t verify

State rules

NONE FOUND

We found no state statute, board rule or enforcement action that names Tesamorelin. The federal position above applies in all 50 states and DC.

What changed at the last check

3 CHANGES
DateFieldWasNowWhy
12 Oct 2026WADA 2026prohibited (S2.2)prohibited (S2.2.4)Named under S2.2.4 growth hormone releasing factors (GHRH analogues). source ↗
12 Oct 2026FL state noteFlorida § 893.03(3) (HB 1041, eff. 2013 10 01) lists tesamorelin and 'GHRH' as Schedule III controlled substances. PosseremovedRemoved. Florida Statutes §893.03 (2025) names no peptide, GHRH analogue or GH secretagogue in Schedule III; the earlier entry was wrong. source ↗
12 Oct 2026TX state noteTexas H&SC § 481.104 reaches HGH analogs (including tesamorelin) via Schedule III equivalent framework; § 481.104(c) barremovedRemoved. Texas lists human growth hormone itself as a controlled substance, but not GHRH analogues or secretagogues; no Texas rule specific to this compound was found. source ↗

Questions

3 ANSWERS
Is Tesamorelin legal in the US?

Yes, as a prescription drug: FDA has approved it (Egrifta). A vial sold as a 'research peptide' is not the approved product, and selling it for human use breaks federal drug law. Pharmacies cannot compound it because it is regulated as a biologic.

Can a pharmacy compound Tesamorelin?

Component of the approved Egrifta products. Tesamorelin moved to the biologics framework in March 2020, and 503A does not cover biological products, so pharmacy compounding of it is not available.

Is Tesamorelin banned in sport?

Yes. It is prohibited at all times under WADA 2026 class S2.2.4. Named under S2.2.4 growth hormone releasing factors (GHRH analogues).

Sources

6 DOCUMENTS
  1. FDA approval record
  2. DEA controlled-substance schedules
  3. FDA 503A compounding position
  4. WADA 2026 Prohibited List
  5. Source for: FL state note
  6. Source for: TX state note
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH